MedTrace Logo

Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia

NCT00900445 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2018-08-07

No results posted yet for this study

Summary

This clinical trial is studying body mass index in younger patients receiving prednisone/prednisolone, vincristine, daunorubicin, and pegaspargase for high-risk acute lymphoblastic leukemia. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the affect of body mass index on the way anticancer drugs work in the body. It may also help doctors predict how patients will respond to treatment

Conditions

Interventions

DRUG

Daunorubicin Hydrochloride

Given IV

OTHER

Pharmacological Study

Correlative studies

DRUG

Prednisolone

Given orally

DRUG

Prednisone

Given orally

DRUG

Vincristine Sulfate

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Ian Pollack · Children's Oncology Group

Eligibility

Min Age
10 Years
Max Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-24
Primary Completion
2009-08-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00900445 on ClinicalTrials.gov